DEA Compliance for Telehealth Ketamine Prescribing

DEA compliance for telehealth ketamine prescribing means a provider holds a valid DEA registration, evaluates the patient in a way that satisfies current federal telemedicine rules, checks the state prescription drug monitoring program, and documents the prescription according to Schedule III controlled substance requirements. The Drug Enforcement Administration (DEA) is the federal agency that regulates the manufacture, distribution, and prescribing of controlled substances under the Controlled Substances Act. Ketamine is classified as a Schedule III controlled substance, meaning it has accepted medical uses but remains subject to federal prescribing rules that do not apply to non-controlled medications. Any provider issuing a ketamine prescription through telemedicine has to work within DEA regulations, and those regulations have shifted substantially since 2020. This article explains what the rules require, how they evolved from the Ryan Haight Act through the DEA's COVID-19 telemedicine exemptions, and what compliant prescribing looks like today.

Ketamine's DEA Classification and Registration Requirement

Ketamine is a Schedule III controlled substance under the Controlled Substances Act, the federal law that sorts drugs into five schedules based on medical use and abuse potential. Schedule III drugs, which also include some anabolic steroids and buprenorphine products, have accepted medical uses and lower abuse potential than Schedule I or II substances, but they still carry federal prescribing, dispensing, and recordkeeping requirements. Ketamine's approved use is as a surgical anesthetic; its use for depression and other psychiatric conditions is off-label, meaning the FDA has not approved it for that purpose even though physicians may prescribe it at their clinical discretion. Every practitioner who prescribes ketamine must hold a current registration with the DEA Diversion Control Division. That registration is tied to a specific practice address, and a prescriber working through a telehealth platform needs their own registration even if the platform is separately registered.

The Ryan Haight Act Baseline

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 set the original rule for prescribing controlled substances through telemedicine: a practitioner generally could not prescribe a Schedule II-V controlled substance to a patient without at least one prior in-person medical evaluation. The law allowed a small set of exceptions.

• The prescription is issued by a hospital or clinic
• The evaluation is conducted via telemedicine while the patient is physically present at a DEA-registered facility with a DEA-registered practitioner
• The practitioner is on duty for the Indian Health Service
• The patient is in a hospital or residential treatment facility

None of these exceptions covered the consumer telehealth model of a patient completing a first evaluation by video from home. Under the original Act, that model was effectively not permitted for controlled substances, including ketamine.

The COVID-19 Exemptions Changed the Model

That changed in March 2020, when the DEA issued blanket exemptions under the federal public health emergency declaration. The exemptions allowed practitioners to prescribe Schedule II-V controlled substances, including Schedule III ketamine, to patients they had not examined in person, as long as the prescription served a legitimate medical purpose and met documentation requirements. This created the legal basis for the direct-to-consumer telehealth ketamine model that exists today. The DEA has extended these flexibilities multiple times since the public health emergency officially ended, and it has continued rulemaking toward a permanent framework, as tracked on HHS's telehealth policy resources. Because the exemption period has been extended repeatedly rather than made permanent, confirm with any prescriber that the practice is currently operating under an active DEA telemedicine flexibility rather than assuming the 2020 exemptions apply indefinitely.

The Path to Permanent Rules

In 2023 the DEA published two proposed rules addressing telemedicine prescribing of controlled substances after the public health emergency: a framework for prescribing Schedule III-V substances without a prior in-person evaluation in certain circumstances, and a special registration pathway for providers meeting specific eligibility criteria. The proposals drew more than 38,000 public comments, telehealth providers argued the restrictions were too tight, and the DEA withdrew them for revision rather than finalizing them. Separately, the SUPPORT Act of 2018 directed the DEA to create a standalone telemedicine prescribing registration for practitioners who meet defined criteria, allowing prescribing without an in-person visit. That registration has been under development for years and has not been finalized. Until either the special registration or a permanent telemedicine rule is finalized, telehealth ketamine prescribing continues to rely on extended DEA exemptions rather than a permanent regulatory framework. See our state regulations overview for how these federal rules interact with state-level telehealth and controlled substance laws.

Provider compliance is not just a legal technicality. It reflects how carefully a telehealth practice evaluates patients, documents care, and monitors for misuse. When choosing a provider, ask directly about DEA registration status, PDMP checks, and recordkeeping practices. To learn how to spot a practice that skips these steps, see our guide to online ketamine clinic red flags. For background on the evaluation and prescribing process itself, see how to get a ketamine prescription online.